Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia. It is also developing various types of cells products, such as synergetic cell precursors, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-403-3409207
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Hemostemix (CVE:HEM) Frequently Asked Questions
What is Hemostemix's stock symbol?
Hemostemix trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HEM."
Has Hemostemix been receiving favorable news coverage?
News stories about HEM stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hemostemix earned a news impact score of -3.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Hemostemix.
Who are some of Hemostemix's key competitors?
Some companies that are related to Hemostemix include Exopharm (EX1), Rhinomed (RNO), Armata Pharmaceuticals (ARMP), Nuformix (NFX), Actinium Pharmaceuticals (ATNM), Medicenna Therapeutics (MDNA), Immunoprecise Antibodies (IPA), Tissue Regenix Group (TRX), Actinium Pharmaceuticals (ATNM), Pharmaust (PAA), Acrux (ACR), Altimmune (ALT), Kazia Therapeutics (KZA), Scancell (SCLP) and Ixico (IXI).
What other stocks do shareholders of Hemostemix own?
Who are Hemostemix's key executives?
Hemostemix's management team includes the folowing people:
- Mr. Kyle Makofka, Chief Exec. Officer
- Ms. Kristin Gulka CPA, CA, Chief Financial Officer
- Ms. Eilat Bain, Director of Operations
- Dr. Alan J. Jacobs, Chief Medical Consultant
How do I buy shares of Hemostemix?
Shares of HEM and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
How big of a company is Hemostemix?
What is Hemostemix's official website?
How can I contact Hemostemix?
Hemostemix's mailing address is Bay 1, PO Box 10, BLACKFALDS, AB T0M 0J0, Canada. The biotechnology company can be reached via phone at +1-403-3409207.
MarketBeat Community Rating for Hemostemix (CVE HEM)
MarketBeat's community ratings are surveys of what our community members think about Hemostemix and other stocks. Vote "Outperform" if you believe HEM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEM will underperform the S&P 500 over the long term. You may vote once every thirty days.
